US and EU filings to follow as Janssen puts simeprevir into Japan’s registration system
This article was originally published in Scrip
Executive Summary
Janssen (a Johnson & Johnson unit) has submitted a regulatory application in Japan for the investigational NS3/4A protease inhibitor, simeprevir (TMC435), for the treatment of genotype 1 hepatitis C patients, triggering a milestone payment of €5 million to partner Medivir.